Moreover, in a study involving the combination of CSF amyloid-β and tau biomarkers in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort, higher CSF t-tau and p-tau and lower CSF Aβ42 were found in Alzheimer’s disease patients. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.